Dermal Equivalents in Oncology: Benefit of One-Stage Procedure.
Fiche publication
Date publication
janvier 2013
Auteurs
Membres identifiés du Cancéropôle Est :
Pr HUMBERT Philippe
Tous les auteurs :
Pauchot J, Elkhyat A, Rolin G, Mac S, Grumblat A, Fotso A, Humbert P, Tropet Y
Lien Pubmed
Résumé
Background In oncology, dermal equivalent may be indicated to cover losses of substance related to skin tumors or after the removal of skin flaps. Objective To report our experience of two dermal equivalents, Matriderm 1 mm with a one-stage graft (DE1) and Integra DL with a two-stage graft (DE2) in oncology. Patients and Method Retrospective, single-center study involving 16 patients. Results Sixteen patients received dermal equivalents as an alternative to flaps (7 cases), over tendinous areas (7 cases), and for cosmetic purposes (2 cases). Twelve patients received DE1 and four DE2. Wound healing times with DE1 were 4 weeks less than those with DE2. Three cases of infection were noted with DE2. The use of dermal equivalents as an alternative to skin flaps was effective, and no adhesions were found over the tendinous areas. Conclusion The learning curve, the two-stage graft required with DE2, and not using a vacuum-assisted closure system can explain the high infection rate. The use of dermal equivalents is particularly indicated in the treatment of skin defect in oncology. The possibility of a one-stage graft with DE1 and combination with negative pressure therapy is beneficial.
Référence
Dermatol Surg. 2013 Jan;39(1 Pt 1):43-50